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AbstrAct
The transcription factor Twist is an important regulator of cranial suture during 
embryogenesis. Closure of the neural tube is achieved via Twist-triggered cellular 
transition from an epithelial to mesenchymal phenotype, a process known as 
epithelial-mesenchymal transition (EMT), characterized by a remarkable increase in 
cell motility. In the absence of Twist activity, EMT and associated phenotypic changes 
in cell morphology and motility can also be induced, albeit moderately, by other 
transcription factor families, including Snail and Zeb. Aberrant EMT triggered by Twist 
in human mammary tumour cells was first reported to drive metastasis to the lung in 
a metastatic breast cancer model. Subsequent analysis of many types of carcinoma 
demonstrated overexpression of these unique EMT transcription factors, which 
statistically correlated with worse outcome, indicating their potential as biomarkers 
in the clinic. However, the mechanisms underlying their activation remain unclear. 
Interestingly, increasing evidence indicates they are selectively activated by distinct 
intracellular kinases, thereby acting as downstream effectors facilitating transduction 
of cytoplasmic signals into nucleus and reprogramming EMT and mesenchymal-
epithelial transition (MET) transcription to control cell plasticity. Understanding 
these relationships and emerging data indicating differential phosphorylation of Twist 
leads to complex and even paradoxical functionalities, will be vital to unlocking their 
potential in clinical settings.
IntroductIon
EMt And sIgnAlIng
EMT is an ancient developmental process that is 
characterized by morphological changes in epithelial cells, 
whereby they acquire a mesenchyme phenotype  [1]. The 
hallmarks of EMT are functionally decreased adhesive 
capacity and increased mobility  [2]. This is facilitated 
by epithelial phenotype changes where cells switch 
from apical-basal polarity to anterior-posterior polarity, 
characteristically illustrated with disrupted intercellular 
junctions and increased migratory potential of individual 
cells. The basis of EMT in physiology is to remove/
replace unnecessary epithelia at specific locations or 
developmental stages. Biochemically, EMT cells exhibit 
distinct patterns of upregulated gene expression of proteins 
engaged in remodeling of cell-cell contact, cytoskeleton, 
and interaction with extracellular matrix (ECM)  [3]. In the 
last two decades, a group of transcription factors including 
the Twist, Snail and Zeb families, have been identified as 
the EMT-inducing transcription factors governing the 
EMT process in vitro, as inducers, enhancers, or both 
[4]. Overexpression of these proteins in untransformed 
mammalian epithelial cells induces potent cell scattering 
phenotypes that also functionally resemble the original 
                                             Review
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EMT in mouse model  [5, 6]. Therefore, the EMT process 
is generally recognized as a reprogramming event 
essentially driven at the transcriptional level, whilst being 
initiated and coupled with ECM signaling  [7, 8] (Figure 
1). 
Many pathways are associated with EMT. One of 
the well-documented signaling axes is the transforming 
growth factor (TGF) cascade  [9] that induces cell 
scattering with increased invasive potential in a variety of 
cancer cells with epithelial origin  [10, 11]. In addition to 
TGFβ, the receptor tyrosine kinases (RTKs) such as EGFR 
family  [12], c-Met  [13], VEGFR  [14, 15], PDGFR 
[16] and others (such as Wnt pathway  [17, 18]) are all 
capable of initiating and/or maintaining EMT phenotypes. 
Importantly, activation of these membrane-associated 
signaling complexes often correlates with elevated 
expression level of the EMT-inducing transcription 
factors, and conversely, in addition to maintaining the 
EMT gene signature, can also maintain and enhance RTK 
signaling through feedback or feed-forward signaling 
loops  [19, 20]. With a particular focus on understanding 
these mechanisms connecting the EMT transcriptional 
response with the activation of the upstream signalosomes, 
a number of studies revealed that three intracellular 
cascades, mTOR/PI3K/Akt, MAPK and Rho GTPases are 
core mediators transducing signals to activate the EMT-
inducing transcription factors  [21-24]. These findings 
have been demonstrated in many types of carcinomas, 
with great consistency  [25]. 
The invasive behaviors of metastatic cancer cells 
closely resemble the physiological EMT phenotypes 
and effectively respond to the known upstream signaling 
cascades. Metastasis initiates with a small portion of the 
cancer cells within the primary organ disseminating from 
the tumor mass and by expressing remarkably high level 
of proteases, digest matrix barriers and subsequently 
invade into surrounding tissues  [26, 27]. Local invasive 
cancer cells further intravasate into lymphatic and/or 
blood vessels and transit to distant organs where they 
extravasate and re-colonize as a metastatic tumour lesion 
[28, 29]. A specific biological impact of the EMT inducers 
in cancer metastasis is demonstrated by depletion of the 
EMT inducers in invasive cancer cells, which significantly 
attenuates the metastatic spread, whilst in most cases 
having little to no effect on the primary tumor growth 
[30]. This indicates that cancer cells preferentially take 
advantage of the physiological EMT signaling to support 
their invasion.
thE plAstIcIty of EMt
Although TGF signaling triggers robust EMT 
activation in epithelial cells, a reversal of the EMT 
phenotype was observed when TGFβ signaling was 
figure 1: plastic epithelial-to-mesenchymal transition. Transcriptional regulation of EMT by activated Twist, Snail and Zeb 
oncogenic proteins is often accompanied with cellular morphological change. EMT: epithelial-mesenchymal transition; MET: mesenchymal-
epithelial transition. Red: high level; blue: low level.
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disrupted by withdrawal  [31] or pharmacological 
inhibition  [32], indicating a high degree of plasticity in 
the EMT process  [33]. In an in vivo orthotopic metastatic 
mouse model, such reversal was discovered in the cancer 
cells that had undergone EMT to colonize and establish 
the metastatic tumour. It was found that the activity of 
Twist was significantly reduced at the initial phase of 
metastatic colonization in the lung and the cancer cells re-
exhibited a classical epithelial phenotype with decreased 
migratory potential, with this process being coined MET 
(mesenchymal-to-epithelial transition)  [34]. In contrast 
to the EMT phenotype which supports the cancer cell 
invasion but restricts their proliferation, MET favors 
re-activation of the proliferative potential, but limits 
invasiveness. In addition to Twist, other EMT inducers also 
displayed downregulated activity during the establishment 
of metastatic growth  [35], and MET was postulated to 
be essential to maintain cancer cell survival in metastatic 
sites  [36, 37]. Moreover, experimental evidence also 
demonstrated that the cells with phenotypic characters 
of EMT antagonize stress-induced apoptosis, including 
resistance to hypoxic pressure and DNA-damaging 
reagents. These observations support a hypothesis that 
the cancer cells with EMT properties potentially possess 
a “stemness” capacity  [38-40], although many aspects 
of this concept are still to be convincingly demonstrated 
[41].
rEgulAtIon of thE EMt-InducIng 
trAnscrIptIon fActor twIst
Considering the interplay between membrane-
associated signaling complexes and EMT-inducing 
transcription factors, as well as the impact of EMT 
on cancer metastasis, it is essential to understand the 
fundamental mechanisms of how signals are transduced 
to activate the EMT inducers such as Twist. Twist belongs 
to the basic helix-loop-helix (bHLH) transcription factor 
family. In mammals, Twist exists as two forms that 
are crucial for proper prenatal development  [42, 43], 
although their functional roles in postnatal physiology are 
still vague. Across species from fruit fly to human, it is 
evolutionarily conserved and recognizes a palindromic-
like consensus sequence CANNTG, also called E-box, 
in the proximal region of promoters. Its binding capacity 
is preferentially mediated through hetero-dimerization 
of Twist with other family members to implement its 
transcriptional regulation  [44]. A recent study employing 
ChIP coupled with high-throughput sequencing for the 
analysis of Twist-binding DNA elements revealed that 
Twist can bind to two tandem E-boxes, a unique feature 
that distinguishes it from other bHLH transcription factors 
[45]. To date, clinical studies have shown evidence to 
support a pro-metastatic role for Twist regulated EMT 
gene expression during cancer progression  [46-49]. This 
includes a number of studies indicating that overexpression 
of Twist enhances carcinoma metastasis  [50, 51] and 
associates with unfavorable clinical prognosis  [52-
55]. Mechanistically, Twist-promoted cancer metastasis 
is mediated through its transcription activity that is 
hijacked by cancer cells  [25]. Twist binding to E-boxes 
can transcriptionally repress E-cadherin expression, and 
consequently disrupts the intercellular adhesion and 
induce single cancer cell dissemination from the primary 
location  [56]. In parallel, Twist overexpression remodels 
cytoskeleton and upregulates several essential signaling 
molecules such as Akt2 and TGFβ2 to robustly induce the 
EMT phenotype  [57]. 
differential phosphorylation of twist as a 
functional switch
Interestingly, TGFβ2 upregulation by Twist can be 
enhanced by Akt-mediated phosphorylation of Twist on 
serine 42 (S42), which increases binding to the TGFβ2 
promoter. Thus, Akt-directed Twist phosphorylation 
on S42 is crucial for the crosstalk between PI3K/Akt 
and TGFβ pathways in metastatic breast cancer  [57] 
and is also demonstrated to be an invasive signature 
in other cancer models  [58]. Not limited to S42 
phosphorylation, independent studies have highlighted 
other phosphorylation sites on Twist including serine 68 
(S68)  [59], serine 18 (S18) and serine 20 (S20)  [60], as 
well as threonine 121 (T121) and serine 123 (S123)  [61] 
that are differentially phosphorylated by MAPK (JNK, 
ERK, p38), casein kinase 2 and Akt, respectively, most 
of which are suggested to activate and/or enhance Twist 
functions through promoting its stability in a context-
dependent manner. Analysis of the protein sequences of 
Twist family members in mammals demonstrates that 
all these crucial phosphorylation sites are evolutionarily 
conserved (Figure 2), implying that the Twist proteins 
across species potentially share a functional homology and 
the two Twist isoforms may display redundant functions. 
Clearly, Twist-phosphorylating kinases are mainly the 
two important intracellular signaling mediators Akt and 
MAPK, both of which are indisputably involved in cell 
proliferation, differentiation and invasion in cancer cells 
and key players of drug resistance in clinic. These two 
nodes can be activated by drivers of EMT and metastasis 
including well-known receptor signaling kinases such 
as TGFβ, RTKs, ECM-mediated integrin pathway and 
canonical or non-canonical WNT signaling, which in turn 
facilitate EMT and cancer metastasis via regulation of 
Akt and MAPK. The increasing evidence demonstrating 
the activity of Twist in regulation of cell migration and 
invasion which are controlled by a posttranslational 
modifications may have many critical implications for 
controlling metastatic lesions, when cancer cells need 
to re-establish high levels of proliferation and growth. 
Intriguingly, the basal level of Twist in non-neoplastic 
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or non-metastatic cells is generally low, indicating that 
Twist activation starts from an activated transcription 
program. To date, it has been shown that dependent upon 
the types of malignancy, Twist can be transcriptionally 
upregulated by NF-κB  [62, 63], STAT3  [64-66], 
DLX4  [67], MYCN and MYC  [68], HMGA2  [69] 
and SOX2  [70],, indicating that activation of Twist is 
a coordinated event between epigenetic transcriptional 
regulation and post-translational modification. Following 
phospho-activation, as a core element involved in the 
activation of transcriptional complexes, Twist can drive 
the transcription of a number of target genes, many of 
which are oncogenic. Although Twist was shown to 
be a transcriptional repressor that inversely correlates 
with E-cadherin expression  [71], it may possibly not 
be directly involved in suppressing CDH1 transcription, 
rather, this is suggested to be mediated by Snail2, a direct 
transcription target downstream of Twist  [72]. It should 
also be noted that the activation of Snail proteins, like 
Twist, is also under the control of phosphorylation  [73]. 
Depending on the upstream kinases, phosphorylated 
Snail may exhibit enhanced repressing activity  [74], or 
rapid degradation  [75]. Direct binding of Snail proteins 
within the regulatory region of CDH1 has been reported 
to mediate its repressing  [76] (Figure 3). Thus, it seems 
that the repression of CDH1 transcription is a sequential 
program controlled by phospho-activated Twist/Snail 
axis. A recent study focusing on the specificity of Twist-
mediated transcription, revealed that Twist dimers can 
uniquely recognized a tandem stretch of E-boxes  [45]. 
The biological consequence of such interaction in relation 
to preferential to transcriptional activation, repression, or 
both, remains to be determined. Undoubtedly, whether any 
related transcriptional specificity is correlated with the 
multifaceted phosphorylation patterns is also an essential 
question.
Inhibition and reversal of twist-induced EMt at 
the site of metastasis
The metastasizing cancer cells displaying an 
EMT phenotype are found to exhibit higher resistance 
to environmental stress  [77, 78]. High expression level 
of EMT signatures observed in circulating invasive 
cells supports survival in the blood stream  [79, 80] , 
allowing subsequent extravasation of these cells from the 
blood or lymphatic vessels and establishment in distant 
organs/tissues. Suppression of the EMT capability in the 
circulating cancer cells can efficiently attenuate the anti-
apoptotic competence  [81]. Therefore, the EMT state 
actively supports cancer cells to overcome environmental 
stress. As mentioned above, the signaling mediators that 
link extracellular signals to EMT inducers often converge 
figure 2: twist structure and phosphorylation conservation in mammals. Twist has three major domains including a 
N-terminal flexible domain, a basic helix-loop-helix domain that is responsible for DNA-binding and a C-terminal Twist-box. Differential 
phosphorylation patterns that have been reported are indicated. In mammals there are two members in Twist family. The phosphorylated 
amino acids highlighted in red are highly conserved in both members across three species (m: mouse; r: rat; h: human). CK2: casein kinase 
2; bHLH: basic helix-loop-helix; T-box: Twist-box.
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to two major signaling nodes PI3K/Akt and MAPK, both 
of which are responsible for drug resistance to clinical 
therapies in many types of cancer  [82]. Indeed, the 
metastatic cancer cells associated with EMT clearly show 
remarkable resistance to a number of small molecular 
inhibitors in clinic  [83-85]. As EMT programming limits 
cell proliferation, it is critical for re-establishing cancer 
cells at the distant metastatic site to overcome this barrier 
for colonization. In this regard, it raises the fundamental 
question of how EMT is revered, or more specifically 
how EMT inducers, such as Twist, are deactivated. Whilst 
further insights are being made, the current understanding 
remains somewhat limited, with changes in Twist stability 
the best described. In different types of cancer cells, Twist 
instability can be induced by changes in microRNA  [86-
88]. In addition to the regulation of Twist stability at RNA 
level, two notable studies suggest that deactivation of Twist 
in metastatic lesion may be triggered by elevated protein 
instability, mediated by either de-phosphorylation of S68 
by the small C-terminal Domain Phosphatase 1  [89], or 
Akt1-directed phosphorylation of Twist on T121 and S123 
that promotes β-TrCP-mediated Twist1 ubiquitination and 
degradation  [90]. These two discoveries elucidate the 
suppression of Twist1 activity through potential kinase-
regulated autonomous feedback signaling and further 
highlights the developing contribution of phosphorylation 
to the regulation of the EMT process. 
figure 3: upstream and downstream regulation of twist. At transcriptional level, NF-κB, STAT3, DLX4, MYCN, MYC, 
HMGA2 and SOX2 have been shown to upregulate Twist in response to the activation of TGFbeta, RTKs, WNT and Integrin pathways. 
Being a central hub, translated Twist undergoes differential phosphorylation directly mediated by Akt, MAPK and CK2 kinases in a 
context-dependent manner. Activation of Twist via phosphorylation triggers oncogenic gene expression such as AKT, TGFB and PDGFR, 
and represses E-cadherin (CDH1), Claudins (CLDN), Raf kinase inhibitor protein (RKIP) and Nephrin1 (NPHS1) that are crucial for 
cell-cell contact through its downstream target Snail, an epigenetic event that actively leads to an reinfoced EMT activation. PTM: post-
translational modification.
Oncotarget62772www.impactjournals.com/oncotarget
dIscussIon
Metastatic spread is a key issue in clinical cancer 
therapy because it represents the major cause of death 
for cancer patients. Many types of invasive cancer with 
epithelial origin represent an advanced EMT phenotype 
that exhibits a high grade of plasticity. Establishment 
and outgrowth of metastases in distant organs primarily 
requires local re-colonization, which is reflected by 
decreased motility and increased proliferation potential 
of the cancer cells. Such reversal from EMT to MET in 
breast cancer-associated metastases was experimentally 
recognized in Twist-induced metastatic models  [34, 
35]. However, the mechanisms of how Twist activity 
is regulated during the establishment of metastases is 
currently undetermined. What factors in the metastatic 
site determine the need of its inactivation? Recent studies 
in mouse model shed some lights on these issues  [90]. 
Cancer cell proliferation in the metastatic site requires high 
level of global Akt activity which is principally capable of 
inducing cell migration, and Twist was reported to inhibit 
environmental stress-triggered senescence  [91, 92]. 
The opposing roles of Akt1 and Akt2 during metastatic 
progression  [93, 94] may provide a ration interpretation 
by proposing a model whereby when cancer cells need 
to disseminate, Akt2-mediated phosphorylation on S42 of 
Twist is dominant; whilst during metastatic colonization, 
Akt1-mediated phosphorylation on T121 and S123 
triggers ubiquitination-dependent degradation of Twist and 
promotes proliferation. This would imply the existence of 
a dynamic pool of Akt isoforms that differentially regulates 
cancer cell behavior at both primary and metastatic sites. 
If this is true in vivo, the predominance of individual Akt 
isoforms will be the fundamental factor to determining the 
cancer cell behavior and fate. Interestingly, independent 
study has shown that Akt isoforms are individually 
regulated by specific microRNAs thus distinguishes the 
spatiotemporal Akt isoforms-contributed activity  [95].
This model whereby Twists oncogenic functions 
are regulated by the predominant Akt isoforms raises 
further crucial questions to be elucidated : 1) what are 
the signals in cancer cells that would control the switch 
of Twist-phosphorylating modulators between the Akt1 
and Akt2 isoforms? 2) How do Akt1 and Akt2 compete 
with each other to impose dominant control of Twist 
phosphorylation? 3) What controls the Akt1 and Akt2 
ratio specifically in the metastatic lesion? These questions 
still remain unanswered and studies have reported 
contradictory observations, including a structural study 
of Twist linking T121 and S123 phosphorylation in 
prostate cancer to Twist mediated metastasis, as opposed 
to Twist degradation  [96]. This discrepancy may indicate 
difference between cancer types or progression stages. 
An explanation for the dominating status of Akt1 and 
Akt2 may be that there exists a feed-back signaling loop 
through multiple signaling cross-talks that eventually 
leads to microRNA-mediated degradation of individual 
Akt isoforms, thereby modulating entire Akt pool activity 
[95, 97]. Alternatively, it is also proposed that distinct 
phosphorylation patterns of Twist require different 
co-activators, which may determine the selectivity of 
phosphorylation motifs on Twist exposed to Akt isoforms. 
In fact, such phospho-specific phenotypes coupled with 
distinct cell fate in cancer have been also found similar to 
other EMT-drivers such as Snail family  [75, 98]. Thus, 
phosphorylation of EMT-promoting molecules seems 
to, at least in part, elaborately act as a functional “on/
off” signal in favor of cancer cell migration, invasion 
and survival. Moreover, on-site de-phosphorylation by 
specific phosphatases could also contribute, either directly 
through targeting Twist, or indirectly by deactivating 
upstream kinases such as tyrosine receptors, to influence 
Twist stability. Insights into this may be found in the 
activity of SHP2 in a well-studied metastasis model, 
which is tremendously increased and promotes metastatic 
colonization  [99]. 
Additionally, more experimental data is needed to 
explore the mechanistic interplay between Twist (and/
or others)-induced EMT and metastasis. A recent study 
challenged the conventional role of Twist-induced EMT 
in promotion of metastasis. In a pancreatic cancer model, 
depletion of Twist or Snail did not inhibit pancreatic 
metastasis; rather, EMT was crucial for the tumors to 
resist to the treatment of DNA-damaging reagents  [100], 
another important notion closely related to current clinical 
cancer therapies  [101, 102]. Moreover, it would be 
interesting to know whether Twist phosphorylation on 
different sites occurs simultaneously, individually or step-
wisely. Does one site phosphorylation/de-phosphorylation 
influence the others? The answers to these questions will 
facilitate a better understanding of the affiliated signaling 
events that regulate the transition between EMT and MET 
during cancer progression, which will greatly facilitate 
development of diagnostic tools for clinical applications. 
Furthermore, such phospho-pattern-specific biomarkers 
may not only predict whether the cancer cells in metastatic 
tumors start a second wave of dissemination, but also be 
considered as potential druggable targets  [103]. 
AcknowlEdgMEnts
We thank Dr. David Restuccia for the critical 
comments and discussions. This work was supported 
by National Natural Science Foundation of China 
Grant 381570056 (to H. Tang), Fondazione Cassa di 
Risparmio di Pistoia&Pescia (ID 154/2014) (to D. Massi), 
Associazione Italiana per la Ricerca sul Cancro (A.I.R.C. 
5xmille Ref. 12237) P.I. A.F. (to M. Mandalà), Swiss 
Cancer Res Foundation Grants KFS-3170-02-2013 and 
KFS-3501-08-2014 (to A. Wicki), and Swiss National 
Science Foundation Grant 31-130838 (to B. A. Hemmings 
and G. Xue). 
Oncotarget62773www.impactjournals.com/oncotarget
conflIcts of IntErEst
The authors declare no potential conflicts of interest.
rEfErEncEs
1. Hay ED. An overview of epithelio-mesenchymal 
transformation. Acta anatomica. 1995; 154(1):8-20.
2. Kalluri R and Weinberg RA. The basics of epithelial-
mesenchymal transition. The Journal of clinical 
investigation. 2009; 119(6):1420-1428.
3. Polyak K and Weinberg RA. Transitions between epithelial 
and mesenchymal states: acquisition of malignant and stem 
cell traits. Nature reviews Cancer. 2009; 9(4):265-273.
4. Sanchez-Tillo E, Liu Y, de Barrios O, Siles L, Fanlo L, 
Cuatrecasas M, Darling DS, Dean DC, Castells A and 
Postigo A. EMT-activating transcription factors in cancer: 
beyond EMT and tumor invasiveness. CMLS. 2012; 
69(20):3429-3456.
5. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey 
JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, 
Vonderheide RH, Leach SD and Stanger BZ. EMT and 
dissemination precede pancreatic tumor formation. Cell. 
2012; 148(1-2):349-361.
6. Cardiff RD. The pathology of EMT in mouse mammary 
tumorigenesis. Journal of mammary gland biology and 
neoplasia. 2010; 15(2):225-233.
7. Wu CY, Tsai YP, Wu MZ, Teng SC and Wu KJ. Epigenetic 
reprogramming and post-transcriptional regulation 
during the epithelial-mesenchymal transition. TIG. 2012; 
28(9):454-463.
8. Kalluri R. EMT: when epithelial cells decide to 
become mesenchymal-like cells. The Journal of clinical 
investigation. 2009; 119(6):1417-1419.
9. Xu J, Lamouille S and Derynck R. TGF-beta-induced 
epithelial to mesenchymal transition. Cell research. 2009; 
19(2):156-172.
10. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, 
Downward J, Beug H and Grunert S. Ras and TGF[beta] 
cooperatively regulate epithelial cell plasticity and 
metastasis: dissection of Ras signaling pathways. The 
Journal of cell biology. 2002; 156(2):299-313.
11. Zavadil J and Bottinger EP. TGF-beta and epithelial-to-
mesenchymal transitions. Oncogene. 2005; 24(37):5764-
5774.
12. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, 
Abbruzzese JL, Hortobagyi GN and Hung MC. Epidermal 
growth factor receptor cooperates with signal transducer 
and activator of transcription 3 to induce epithelial-
mesenchymal transition in cancer cells via up-regulation 
of TWIST gene expression. Cancer research. 2007; 
67(19):9066-9076.
13. Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa 
H, Tanaka K, Mohri Y, Inoue Y, Goel A and Kusunoki 
M. Co-expression of hepatocyte growth factor and c-Met 
predicts peritoneal dissemination established by autocrine 
hepatocyte growth factor/c-Met signaling in gastric cancer. 
International journal of cancer. 2012; 130(12):2912-2921.
14. Fantozzi A, Gruber DC, Pisarsky L, Heck C, Kunita 
A, Yilmaz M, Meyer-Schaller N, Cornille K, Hopfer 
U, Bentires-Alj M and Christofori G. VEGF-mediated 
angiogenesis links EMT-induced cancer stemness to tumor 
initiation. Cancer research. 2014; 74(5):1566-1575.
15. Gonzalez-Moreno O, Lecanda J, Green JE, Segura V, 
Catena R, Serrano D and Calvo A. VEGF elicits epithelial-
mesenchymal transition (EMT) in prostate intraepithelial 
neoplasia (PIN)-like cells via an autocrine loop. 
Experimental cell research. 2010; 316(4):554-567.
16. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, 
Capodiecci P, Donovan M, Cordon-Cardo C, Beug H and 
Grunert S. Autocrine PDGFR signaling promotes mammary 
cancer metastasis. The Journal of clinical investigation. 
2006; 116(6):1561-1570.
17. Chang YW, Su YJ, Hsiao M, Wei KC, Lin WH, Liang 
CL, Chen SC and Lee JL. Diverse Targets of beta-Catenin 
during the Epithelial-Mesenchymal Transition Define 
Cancer Stem Cells and Predict Disease Relapse. Cancer 
research. 2015; 75(16):3398-3410.
18. Xue G, Romano E, Massi D and Mandala M. Wnt/beta-
catenin signaling in melanoma: Preclinical rationale and 
novel therapeutic insights. Cancer treatment reviews. 2016; 
49:1-12.
19. Sosic D, Richardson JA, Yu K, Ornitz DM and Olson 
EN. Twist regulates cytokine gene expression through a 
negative feedback loop that represses NF-kappaB activity. 
Cell. 2003; 112(2):169-180.
20. Eckert MA and Yang J. Targeting invadopodia to block 
breast cancer metastasis. Oncotarget. 2011; 2(7):562-568. 
doi:  10.18632/oncotarget.301
21. Larue L and Bellacosa A. Epithelial-mesenchymal transition 
in development and cancer: role of phosphatidylinositol 3’ 
kinase/AKT pathways. Oncogene. 2005; 24(50):7443-7454.
22. Siegel PM and Massague J. Cytostatic and apoptotic actions 
of TGF-beta in homeostasis and cancer. Nature reviews 
Cancer. 2003; 3(11):807-821.
23. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, 
Huang J, Gleave M and Wu H. Pten loss and RAS/MAPK 
activation cooperate to promote EMT and metastasis 
initiated from prostate cancer stem/progenitor cells. Cancer 
research. 2012; 72(7):1878-1889.
24. Thiery JP. Epithelial-mesenchymal transitions in tumour 
progression. Nature reviews Cancer. 2002; 2(6):442-454.
25. De Craene B and Berx G. Regulatory networks defining 
EMT during cancer initiation and progression. Nature 
reviews Cancer. 2013; 13(2):97-110.
26. Keirsse J, Laoui D, Van Overmeire E and Van Ginderachter 
JA. Targeting cell-intrinsic and cell-extrinsic mechanisms 
of intravasation in invasive breast cancer. Science signaling. 
Oncotarget62774www.impactjournals.com/oncotarget
2014; 7(353):pe28.
27. Kim J, Yu W, Kovalski K and Ossowski L. Requirement 
for specific proteases in cancer cell intravasation as revealed 
by a novel semiquantitative PCR-based assay. Cell. 1998; 
94(3):353-362.
28. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris 
VL, Chambers AF and Groom AC. Multistep nature of 
metastatic inefficiency: dormancy of solitary cells after 
successful extravasation and limited survival of early 
micrometastases. The American journal of pathology. 1998; 
153(3):865-873.
29. Nguyen DX, Bos PD and Massague J. Metastasis: from 
dissemination to organ-specific colonization. Nature 
reviews Cancer. 2009; 9(4):274-284.
30. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson 
RA, Come C, Savagner P, Gitelman I, Richardson A and 
Weinberg RA. Twist, a master regulator of morphogenesis, 
plays an essential role in tumor metastasis. Cell. 2004; 
117(7):927-939.
31. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley 
DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals 
PJ, Koteliansky V and Arteaga CL. Blockade of TGF-
beta inhibits mammary tumor cell viability, migration, and 
metastases. The Journal of clinical investigation. 2002; 
109(12):1551-1559.
32. Gal A, Sjoblom T, Fedorova L, Imreh S, Beug H and 
Moustakas A. Sustained TGF beta exposure suppresses 
Smad and non-Smad signalling in mammary epithelial 
cells, leading to EMT and inhibition of growth arrest and 
apoptosis. Oncogene. 2008; 27(9):1218-1230.
33. Nieto MA and Cano A. The epithelial-mesenchymal 
transition under control: global programs to regulate 
epithelial plasticity. Seminars in cancer biology. 2012; 
22(5-6):361-368.
34. Tsai JH, Donaher JL, Murphy DA, Chau S and Yang J. 
Spatiotemporal regulation of epithelial-mesenchymal 
transition is essential for squamous cell carcinoma 
metastasis. Cancer cell. 2012; 22(6):725-736.
35. Ocana OH, Corcoles R, Fabra A, Moreno-Bueno G, 
Acloque H, Vega S, Barrallo-Gimeno A, Cano A and Nieto 
MA. Metastatic colonization requires the repression of the 
epithelial-mesenchymal transition inducer Prrx1. Cancer 
cell. 2012; 22(6):709-724.
36. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson 
EW and Williams ED. Mesenchymal-to-epithelial 
transition facilitates bladder cancer metastasis: role of 
fibroblast growth factor receptor-2. Cancer research. 2006; 
66(23):11271-11278.
37. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, 
Celia-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua 
Y, Wei Y, Hu G, Garcia BA, et al. Direct targeting of 
Sec23a by miR-200s influences cancer cell secretome and 
promotes metastatic colonization. Nature medicine. 2011; 
17(9):1101-1108.
38. Medema JP. Cancer stem cells: the challenges ahead. 
Nature cell biology. 2013; 15(4):338-344.
39. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou 
AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, 
Campbell LL, Polyak K, Brisken C, et al. The epithelial-
mesenchymal transition generates cells with properties of 
stem cells. Cell. 2008; 133(4):704-715.
40. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S 
and Puisieux A. Generation of breast cancer stem cells 
through epithelial-mesenchymal transition. PloS one. 2008; 
3(8):e2888.
41. Beck B, Lapouge G, Rorive S, Drogat B, Desaedelaere K, 
Delafaille S, Dubois C, Salmon I, Willekens K, Marine JC 
and Blanpain C. Different levels of Twist1 regulate skin 
tumor initiation, stemness, and progression. Cell stem cell. 
2015; 16(1):67-79.
42. Kang Y and Massague J. Epithelial-mesenchymal 
transitions: twist in development and metastasis. Cell. 2004; 
118(3):277-279.
43. Rice DP, Aberg T, Chan Y, Tang Z, Kettunen PJ, 
Pakarinen L, Maxson RE and Thesleff I. Integration of 
FGF and TWIST in calvarial bone and suture development. 
Development. 2000; 127(9):1845-1855.
44. Castanon I, Von Stetina S, Kass J and Baylies MK. 
Dimerization partners determine the activity of the Twist 
bHLH protein during Drosophila mesoderm development. 
Development. 2001; 128(16):3145-3159.
45. Chang AT, Liu Y, Ayyanathan K, Benner C, Jiang Y, 
Prokop JW, Paz H, Wang D, Li HR, Fu XD, Rauscher 
FJ, 3rd and Yang J. An evolutionarily conserved DNA 
architecture determines target specificity of the TWIST 
family bHLH transcription factors. Genes & development. 
2015; 29(6):603-616.
46. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, 
Wang XH, Wong YC, Guan XY, Man K, Chau KL 
and Fan ST. Twist overexpression correlates with 
hepatocellular carcinoma metastasis through induction of 
epithelial-mesenchymal transition. Clin cancer res. 2006; 
12(18):5369-5376.
47. Sossey-Alaoui K, Pluskota E, Davuluri G, Bialkowska K, 
Das M, Szpak D, Lindner DJ, Downs-Kelly E, Thompson 
CL and Plow EF. Kindlin-3 enhances breast cancer 
progression and metastasis by activating Twist-mediated 
angiogenesis. FASEB journal. 2014; 28(5):2260-2271.
48. Puisieux A, Valsesia-Wittmann S and Ansieau S. A twist 
for survival and cancer progression. British journal of 
cancer. 2006; 94(1):13-17.
49. Thiery JP and Morgan M. Breast cancer progression with a 
Twist. Nature medicine. 2004; 10(8):777-778.
50. Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato 
Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F, Ma J, 
Salih T, Cades J, et al. The twist box domain is required 
for Twist1-induced prostate cancer metastasis. MCR. 2013; 
11(11):1387-1400.
Oncotarget62775www.impactjournals.com/oncotarget
51. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, 
Masubuchi D, Eto M, Uchiumi T and Naito S. Castration 
resistance of prostate cancer cells caused by castration-
induced oxidative stress through Twist1 and androgen 
receptor overexpression. Oncogene. 2010; 29(2):237-250.
52. Shibata K, Kajiyama H, Ino K, Terauchi M, Yamamoto E, 
Nawa A, Nomura S and Kikkawa F. Twist expression in 
patients with cervical cancer is associated with poor disease 
outcome. Annals of oncology. 2008; 19(1):81-85.
53. Kajiyama H, Shibata K, Umezu T, Mizuno M, Suzuki S, 
Yamamoto E, Fujiwara S and Kikkawa F. Expression of 
Twist enhances risk of poor oncologic outcome in patients 
with stage Ib to II cervical carcinoma with lymphovascular 
space involvement. Human pathology. 2013; 44(2):181-
188.
54. Nordfors K, Haapasalo J, Makela K, Granberg KJ, Nykter 
M, Korja M, Paavonen T, Haapasalo H and Soini Y. Twist 
predicts poor outcome of patients with astrocytic glioma. 
Journal of clinical pathology. 2015; 68(11):905-912.
55. Pereira L, Horta S, Mateus R and Videira MA. Implications 
of Akt2/Twist crosstalk on breast cancer metastatic 
outcome. Drug discovery today. 2015; 20(9):1152-1158.
56. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and 
Weinberg RA. Loss of E-cadherin promotes metastasis 
via multiple downstream transcriptional pathways. Cancer 
research. 2008; 68(10):3645-3654.
57. Xue G, Restuccia DF, Lan Q, Hynx D, Dirnhofer S, Hess 
D, Ruegg C and Hemmings BA. Akt/PKB-mediated 
phosphorylation of Twist1 promotes tumor metastasis via 
mediating cross-talk between PI3K/Akt and TGF-beta 
signaling axes. Cancer discovery. 2012; 2(3):248-259.
58. Mammoto T, Jiang A, Jiang E and Mammoto A. The Role 
of Twist1 Phosphorylation in Angiogenesis and Pulmonary 
Fibrosis. American journal of respiratory cell and molecular 
biology. 2016.
59. Hong J, Zhou J, Fu J, He T, Qin J, Wang L, Liao L and 
Xu J. Phosphorylation of serine 68 of Twist1 by MAPKs 
stabilizes Twist1 protein and promotes breast cancer cell 
invasiveness. Cancer research. 2011; 71(11):3980-3990.
60. Su YW, Xie TX, Sano D and Myers JN. IL-6 stabilizes 
Twist and enhances tumor cell motility in head and neck 
cancer cells through activation of casein kinase 2. PloS one. 
2011; 6(4):e19412.
61. Lu S, Nie J, Luan Q, Feng Q, Xiao Q, Chang Z, Shan C, 
Hess D, Hemmings BA and Yang Z. Phosphorylation of the 
Twist1-family basic helix-loop-helix transcription factors 
is involved in pathological cardiac remodeling. PloS one. 
2011; 6(4):e19251.
62. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, 
Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff 
AM, et al. Epithelial-mesenchymal transition induced by 
TNF-alpha requires NF-kappaB-mediated transcriptional 
upregulation of Twist1. Cancer research. 2012; 72(5):1290-
1300.
63. Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa S, 
Kuntzen C and Franzoso G. Upregulation of Twist-1 by NF-
kappaB blocks cytotoxicity induced by chemotherapeutic 
drugs. Molecular and cellular biology. 2007; 27(11):3920-
3935.
64. Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, 
Mansour M, Xu LM, Costanzo C, Cheng JQ and Wang LH. 
Twist is transcriptionally induced by activation of STAT3 
and mediates STAT3 oncogenic function. The Journal of 
biological chemistry. 2008; 283(21):14665-14673.
65. Hsu KW, Hsieh RH, Huang KH, Fen-Yau Li A, Chi CW, 
Wang TY, Tseng MJ, Wu KJ and Yeh TS. Activation of 
the Notch1/STAT3/Twist signaling axis promotes gastric 
cancer progression. Carcinogenesis. 2012; 33(8):1459-
1467.
66. Cho KH, Jeong KJ, Shin SC, Kang J, Park CG and Lee 
HY. STAT3 mediates TGF-beta1-induced TWIST1 
expression and prostate cancer invasion. Cancer letters. 
2013; 336(1):167-173.
67. Zhang L, Yang M, Gan L, He T, Xiao X, Stewart MD, Liu 
X, Yang L, Zhang T, Zhao Y and Fu J. DLX4 upregulates 
TWIST and enhances tumor migration, invasion and 
metastasis. International journal of biological sciences. 
2012; 8(8):1178-1187.
68. Selmi A, de Saint-Jean M, Jallas AC, Garin E, Hogarty MD, 
Benard J, Puisieux A, Marabelle A and Valsesia-Wittmann 
S. TWIST1 is a direct transcriptional target of MYCN and 
MYC in neuroblastoma. Cancer letters. 2015; 357(1):412-
418.
69. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin 
CH and Moustakas A. Transforming growth factor-
beta employs HMGA2 to elicit epithelial-mesenchymal 
transition. The Journal of cell biology. 2006; 174(2):175-
183.
70. Bisaro B, Montani M, Konstantinidou G, Marchini C, 
Pietrella L, Iezzi M, Galie M, Orso F, Camporeale A, 
Colombo SM, Di Stefano P, Tornillo G, Camacho-Leal 
MP, et al. p130Cas/Cyclooxygenase-2 axis in the control of 
mesenchymal plasticity of breast cancer cells. BCR. 2012; 
14(5):R137.
71. Vesuna F, van Diest P, Chen JH and Raman V. Twist is 
a transcriptional repressor of E-cadherin gene expression 
in breast cancer. Biochemical and biophysical research 
communications. 2008; 367(2):235-241.
72. Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe 
CJ and Yang J. Snail2 is an essential mediator of Twist1-
induced epithelial mesenchymal transition and metastasis. 
Cancer research. 2011; 71(1):245-254.
73. Dominguez D, Montserrat-Sentis B, Virgos-Soler A, Guaita 
S, Grueso J, Porta M, Puig I, Baulida J, Franci C and Garcia 
de Herreros A. Phosphorylation regulates the subcellular 
location and activity of the snail transcriptional repressor. 
Molecular and cellular biology. 2003; 23(14):5078-5089.
74. Yang Z, Rayala S, Nguyen D, Vadlamudi RK, Chen S and 
Oncotarget62776www.impactjournals.com/oncotarget
Kumar R. Pak1 phosphorylation of snail, a master regulator 
of epithelial-to-mesenchyme transition, modulates snail’s 
subcellular localization and functions. Cancer research. 
2005; 65(8):3179-3184.
75. Zheng H, Shen M, Zha YL, Li W, Wei Y, Blanco MA, 
Ren G, Zhou T, Storz P, Wang HY and Kang Y. PKD1 
phosphorylation-dependent degradation of SNAIL by SCF-
FBXO11 regulates epithelial-mesenchymal transition and 
metastasis. Cancer cell. 2014; 26(3):358-373.
76. Ko H, Kim HS, Kim NH, Lee SH, Kim KH, Hong SH and 
Yook JI. Nuclear localization signals of the E-cadherin 
transcriptional repressor Snail. Cells, tissues, organs. 2007; 
185(1-3):66-72.
77. Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I and 
Nieto MA. Snail blocks the cell cycle and confers resistance 
to cell death. Genes & development. 2004; 18(10):1131-
1143.
78. Gupta GP and Massague J. Cancer metastasis: building a 
framework. Cell. 2006; 127(4):679-695.
79. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R and 
Kasimir-Bauer S. Stem cell and epithelial-mesenchymal 
transition markers are frequently overexpressed in 
circulating tumor cells of metastatic breast cancer patients. 
BCR. 2009; 11(4):R46.
80. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting 
RL, Turnbull JD, Herold CI, Marcom PK, George DJ and 
Garcia-Blanco MA. Circulating tumor cells from patients 
with advanced prostate and breast cancer display both 
epithelial and mesenchymal markers. MCR. 2011; 9(8):997-
1007.
81. Labelle M, Begum S and Hynes RO. Direct signaling 
between platelets and cancer cells induces an epithelial-
mesenchymal-like transition and promotes metastasis. 
Cancer cell. 2011; 20(5):576-590.
82. Wicki A, Mandala M, Massi D, Taverna D, Tang H, 
Hemmings BA and Xue G. Acquired Resistance to Clinical 
Cancer Therapy: A Twist in Physiological Signaling. 
Physiological reviews. 2016; 96(3):805-829.
83. Singh A and Settleman J. EMT, cancer stem cells and drug 
resistance: an emerging axis of evil in the war on cancer. 
Oncogene. 2010; 29(34):4741-4751.
84. Dave B, Mittal V, Tan NM and Chang JC. Epithelial-
mesenchymal transition, cancer stem cells and treatment 
resistance. BCR. 2012; 14(1):202.
85. Voulgari A and Pintzas A. Epithelial-mesenchymal 
transition in cancer metastasis: mechanisms, markers 
and strategies to overcome drug resistance in the clinic. 
Biochimica et biophysica acta. 2009; 1796(2):75-90.
86. Zhao X, Wang Y, Deng R, Zhang H, Dou J, Yuan H, Hou 
G, Du Y, Chen Q and Yu J. miR186 suppresses prostate 
cancer progression by targeting Twist1. Oncotarget. 2016. 
doi: 10.18632/oncotarget.8887.
87. Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, Zhang 
ZJ, Peng YH, Yang YZ and Yun JP. miR-720 inhibits 
tumor invasion and migration in breast cancer by targeting 
TWIST1. Carcinogenesis. 2014; 35(2):469-478.
88. Wang Y, Sun B, Zhao X, Zhao N, Sun R, Zhu D, Zhang 
Y, Li Y, Gu Q, Dong X, Wang M and An J. Twist1-
related miR-26b-5p suppresses epithelial-mesenchymal 
transition, migration and invasion by targeting SMAD1 in 
hepatocellular carcinoma. Oncotarget. 2016; 7(17):24383-
24401. doi: 10.18632/oncotarget.8328.
89. Sun T, Fu J, Shen T, Lin X, Liao L, Feng XH and Xu J. 
The Small C-terminal Domain Phosphatase 1 Inhibits 
Cancer Cell Migration and Invasion by Dephosphorylating 
Phospho-Ser68-Twist1 to Accelerate Twist1 Degradation. 
The Journal of biological chemistry. 2016.
90. Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai 
CC, Chang SS, Hsu YH, Sun HL, Kim J, Yamaguchi H, et 
al. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in 
Breast Cancer through Phosphorylation-Dependent Twist1 
Degradation. Cancer research. 2016; 76(6):1451-1462.
91. Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, 
Zabuawala T, Chen J, Cho YJ, Luong R, Tamayo P, Salih 
T, Aziz K, Adam SJ, et al. Twist1 suppresses senescence 
programs and thereby accelerates and maintains mutant 
Kras-induced lung tumorigenesis. PLoS genetics. 2012; 
8(5):e1002650.
92. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, 
Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, 
Maestro R, Voeltzel T, Selmi A, et al. Induction of EMT 
by twist proteins as a collateral effect of tumor-promoting 
inactivation of premature senescence. Cancer cell. 2008; 
14(1):79-89.
93. Xue G and Hemmings BA. PKB/Akt-dependent regulation 
of cell motility. Journal of the National Cancer Institute. 
2013; 105(6):393-404.
94. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran 
P, Kothari N, Natesan S and Brugge JS. Distinct roles of 
Akt1 and Akt2 in regulating cell migration and epithelial-
mesenchymal transition. The Journal of cell biology. 2005; 
171(6):1023-1034.
95. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis 
F, Maroulakou IG, Struhl K and Tsichlis PN. MicroRNAs 
differentially regulated by Akt isoforms control EMT and 
stem cell renewal in cancer cells. Science signaling. 2009; 
2(92):ra62.
96. Gajula RP, Chettiar ST, Williams RD, Nugent K, Kato Y, 
Wang H, Malek R, Taparra K, Cades J, Annadanam A, 
Yoon AR, Fertig E, Firulli BA, et al. Structure-function 
studies of the bHLH phosphorylation domain of TWIST1 
in prostate cancer cells. Neoplasia. 2015; 17(1):16-31.
97. Sanidas I, Polytarchou C, Hatziapostolou M, Ezell SA, 
Kottakis F, Hu L, Guo A, Xie J, Comb MJ, Iliopoulos D 
and Tsichlis PN. Phosphoproteomics screen reveals akt 
isoform-specific signals linking RNA processing to lung 
cancer. Molecular cell. 2014; 53(4):577-590.
Oncotarget62777www.impactjournals.com/oncotarget
98. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M and 
Hung MC. Dual regulation of Snail by GSK-3beta-mediated 
phosphorylation in control of epithelial-mesenchymal 
transition. Nature cell biology. 2004; 6(10):931-940.
99. Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-
Baron G, Mazzarol G, Confalonieri S, Quarto M, Hu G, 
Balwierz PJ, Pachkov M, Elledge SJ, van Nimwegen 
E, et al. Tyrosine phosphatase SHP2 promotes breast 
cancer progression and maintains tumor-initiating cells 
via activation of key transcription factors and a positive 
feedback signaling loop. Nature medicine. 2012; 18(4):529-
537.
100. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, 
Sugimoto H, Wu CC, LeBleu VS and Kalluri R. Epithelial-
to-mesenchymal transition is dispensable for metastasis but 
induces chemoresistance in pancreatic cancer. Nature. 2015; 
527(7579):525-530.
101. Mitra A, Mishra L and Li S. EMT, CTCs and CSCs in 
tumor relapse and drug-resistance. Oncotarget. 2015; 
6(13):10697-10711. doi:  10.18632/oncotarget.4037
102. Wilson C, Nicholes K, Bustos D, Lin E, Song Q, Stephan 
JP, Kirkpatrick DS and Settleman J. Overcoming EMT-
associated resistance to anti-cancer drugs via Src/FAK 
pathway inhibition. Oncotarget. 2014; 5(17):7328-7341. 
doi:  10.18632/oncotarget.2397
103. Marcucci F, Stassi G and De Maria R. Epithelial-
mesenchymal transition: a new target in anticancer drug 
discovery. Nature reviews Drug discovery. 2016; 15(5):311-
325.
